prmt5

PRMT5-IN-1 is a covalent inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50 of 11 nM for PRMT5/MEP50).

PRMT5-IN-2 is an inhibitor of protein arginine methyltransferase 5.

PRMT5-IN-14 is a PRMT5 inhibitor used to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

PRMT5-IN-13 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5).

PRMT5-IN-15, a PRMT5 inhibitor, has an IC50 value of 0.84 nM.

PRMT5-IN-11 demonstrates potent structure-dependent inhibition against the protein methyltransferase PRMT5:MEP50 complex at submicromolar concentrations.

PRMT5-IN-12 demonstrates significant inhibitory activity on PRMT5.

PRMT5-IN-9 is a novel PRMT5 inhibitor for treating cancer, with an IC50 of 0.01 μM.

MRTX-1719 is a potent and selective inhibitor of the PRMT5/MTA complex with an IC50 value of <10 nM against PRMT5/MTAMTAPDELSDMA cell lines.

CMP-5 is a PRMT5 inhibitor with antiviral activity, inhibits PRMT5 methyltransferase activity, and can be used in the study of SARS virus infection.

DW14800 is an inhibitor of PRMT5 (IC50 = 17 nM), enhances the transcription of HNF4α, and reduces the level of H4R3me2s.

(Iso)-MS4322 ((Iso)-YS43-22) is a selective and potent protein arginine methyltransferase 5 (PRMT5) degrader with potential anticancer activity that effectively reduces PRMT5 protein levels in MCF-7 cells and inhibits the growth of a wide range of cancer cells.

GSK3326595 (EPZ015938) is an inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50:6.2 nM.).

AGI-24512 is a potent inhibitor of methionine adenylyltransferase 2α (MAT2A) (IC50: 8 nM).AGI-24512 shows antiproliferative activity in MTAP-deficient cancer cells.AGI-24512 inhibits MAT2A, which causes DNA damage in MTAP, and is often used in conjunction with anticancer compounds in cancer research.

JNJ-64619178 is a selective, orally active, and pseudo-irreversible inhibitor of protein arginine methyltransferase 5 (IC50: 0.14 nM). It has effective activity In lung cancer.

LLY-283 is a potent, selective, and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, exhibiting an IC50 of 22 nM and a Kd of 6 nM for the PRMT5:MEP50 complex, and demonstrates antitumor activity.

EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 enzymatic activity.

GSK591 (GSK3203591), Alternative Names are EPZ015866, GSK3203591, is a potent selective inhibitor of the arginine methyltransferase PRMT5 (IC50=11 nM).

HLCL-61 hydrochloride (HLCL-61 HCL) is a potent and selective PRMT5 inhibitor for the treatment of acute myeloid leukemia.

TNG908 is an orally active and selective MTAP-co-PRMT5 inhibitor that crosses the blood-brain barrier and kills MTAP-deficient cancers.

AMG-193 is an inhibitor of the MTA-PRMT5 complex and is used in the study of cancer, respiratory diseases and digestive disorders.

BRD0639 is a pioneering inhibitor targeting the interaction between PRMT5 and its substrate adaptor. As a competitive inhibitor of the PRMT5 binding motif (PBM), BRD0639 facilitates the investigation of activities dependent on PBM-associated PRMT5 functions [1].

MRTX-9768 is a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors.

BLL5 Maleate (PRMT5-IN-20) is a selective PRMT5 inhibitor that blocks EBV-driven B-cell transformation and survival without affecting normal B cells.